Researchmoz presents this most up-to-date research on"Research
Announces Pharmaceutical Market - Brazil, United Kingdom and Russia
Report At Researchmoz.us". The report focuses primarily on quantitative
market metrics in order to characterize the growth and evolution of the
Remote Patient Monitoring Market.
The Pharmaceutical Market: Brazil http://www.researchmoz.us/the-pharmaceutical-market-brazil-report.html
The
Brazilian pharmaceutical market remains our favourite regional market
in Latin America due to its large market size and strong domestic demand
for innovative, high-tech products. The government i s increasing ly
invest ing in the healthcare sector and pharmaceutical industry to
reduce the financial burden of diseases , and the country's private
healthcare sectors provide opportunities for foreign companies. However,
the increasing d rug rebate level has significantly undermined the
profits recorded by generic drugmakers. The more aggressive government
techonology transfer deals with multinationals as well as the drug
approval delays due to bureaucracy and staff shortages at ANVISA have
also dampened multinationals' revenue-generating opportunities.The
competitive landscape section provides comparative company analyses and
rankings by US$ sales and % share of total sales - for the total
pharmaceutical sector, as well as the OTC, generics, and distribution
sub-sectors.
The Pharmaceutical Market: United Kingdom http://www.researchmoz.us/the-pharmaceutical-market-united-kingdom-report.html
Drugmakers
and governments will increasingly enter agreements that provide some
form of risk- sharing or price protection for new drugs. Since most
European governments, including the UK authorities, are focussing on
cost containment in the healthcare sector, alternative pricing schemes
for medicines allow for budget control, as well as providing patients
with access to highly innovative treatments. Guidance drafted by the
National Institute for Health and Clinical Excellence (NICE) has
recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and
Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin
cancer. These are the first new drugs approved for routine use by the
UK's National Health Service for the disease in more than a decade.
While this is positive news for both drugmakers, NICE's stamp of
approval came only after the manufacturers of both drugs agreed to offer
discounts, overturning a prior rejection of the treatments by the
watchdog.The competitive landscape section provides comparative company
analyses and rankings by US$ sales and % share of total sales - for the
total pharmaceutical sector, as well as the OTC, generics, and
distribution sub-sectors.Pharmaceuticals: GBP23.81bn (US$38.33bn) in
2011 to GBP23.74bn (US$37.27bn) in 2012; -0.3% in local currency terms
and -2.8% in US dollar terms. Forecast unchanged from Q4 12.Healthcare:
GBP144.79bn (US$232.99bn) in 2011 to GBP149.35bn (US$234.48bn) in 2012;
+3.2% in local currency terms and +0.6% in US dollar terms. Forecast
unchanged from Q4 12.Medical devices: GBP5.89bn (US$9.48nn) in 2011 to
GBP5.93bn (US$9.30bn) in 2012; +0.6% in local currency terms and -1.9%
in US dollar terms. Forecast unchanged from Q4 12.
The Pharmaceutical Market: Russia http://www.researchmoz.us/the-pharmaceutical-market-russia-report.html
The
Russian pharmaceutical market remains a powerhouse in the Emerging
Europe region . The country has by far the larg est population in the
region. I ts resource s -driven economic growth is funding both private
and public spending on medicines and healthcare services. The country's
World Trade Organisation (WTO) accession has eliminated tariff barriers
and should, in the long run, drive major improvements in a problematic
intellectual property environment.Both domestic and cross-border mergers
and acquisitions (M&A) activity has picked up since the 2009
economic crisis, a result of increased incentives for local production
under the government's industrial policy for the sector and the need for
scale to compete , especially in the generic medicines market. We
believe a critical forward step for the market will be the successful
implementation of a broad-based medicines insurance programme in the
next few years, following current pilot projects. If this proves
successful, we would expect growth to outstrip our current five-year
projection for a compound annual growth rate of 8.3% in US dollar terms
during the period 2012-2017.The competitive landscape section provides
comparative company analyses and rankings by US$ sales and % share of
total sales - for the total pharmaceutical sector, as well as the OTC,
generics, and distribution sub-sectors.
For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
word press : http://marketresearchtopix.wordpress.com
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
word press : http://marketresearchtopix.wordpress.com
0 comments:
Post a Comment